{"title":"Can Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis be Treated More Successfully?","authors":"K L Holloway-Kew, M Henneberg","doi":"10.1002/puh2.70363","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Signs and symptoms of tuberculosis (TB) are a result of a disturbed balance between <i>Mycobacterium tuberculosis</i> and the patient's tolerance to its pathogenic properties. Pharmacological treatments elicit the evolution of drug resistance, and there is a need to consider alternative treatment methods. We performed a statistical analysis of World Health Organization (WHO) data, combined with an analysis of old medical records, aimed at suggesting a new treatment.</p><p><strong>Methods: </strong>Data from the WHO for all countries worldwide (<i>N</i> = 215) on the epidemiology of all TB cases, human immunodeficiency virus (HIV)-related TB, multidrug-resistant TB (MDR) and extensively drug-resistant TB (XDR) in 2012-2022 contain prevalence, success rate of treatment, mortality and numbers of failed treatments and patients lost-to-follow-up. Data on success rates in old 'sanatoria treatment', widespread before the 1940s, were used to predict hypothetical success rates of drug-resistant cases if sanatoria treatment were added to treatment regimes.</p><p><strong>Results: </strong>After 2012, the number of MDR and XDR cases increased faster than the total number of TB cases, as did their proportions among the total. Success rates of MDR (∼70%) and XDR (around 60%) treatments would hypothetically increase to around 90%, when supplemented by sanatoria treatment success.</p><p><strong>Conclusions: </strong>Adding treatments for increasing tolerance to TB infection to the current pharmacological treatments may improve outcomes.</p>","PeriodicalId":74613,"journal":{"name":"Public health challenges","volume":"5 3","pages":"e70363"},"PeriodicalIF":1.8000,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13577933/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public health challenges","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/puh2.70363","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Signs and symptoms of tuberculosis (TB) are a result of a disturbed balance between Mycobacterium tuberculosis and the patient's tolerance to its pathogenic properties. Pharmacological treatments elicit the evolution of drug resistance, and there is a need to consider alternative treatment methods. We performed a statistical analysis of World Health Organization (WHO) data, combined with an analysis of old medical records, aimed at suggesting a new treatment.
Methods: Data from the WHO for all countries worldwide (N = 215) on the epidemiology of all TB cases, human immunodeficiency virus (HIV)-related TB, multidrug-resistant TB (MDR) and extensively drug-resistant TB (XDR) in 2012-2022 contain prevalence, success rate of treatment, mortality and numbers of failed treatments and patients lost-to-follow-up. Data on success rates in old 'sanatoria treatment', widespread before the 1940s, were used to predict hypothetical success rates of drug-resistant cases if sanatoria treatment were added to treatment regimes.
Results: After 2012, the number of MDR and XDR cases increased faster than the total number of TB cases, as did their proportions among the total. Success rates of MDR (∼70%) and XDR (around 60%) treatments would hypothetically increase to around 90%, when supplemented by sanatoria treatment success.
Conclusions: Adding treatments for increasing tolerance to TB infection to the current pharmacological treatments may improve outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
